IN2015DN03733A - - Google Patents
Info
- Publication number
- IN2015DN03733A IN2015DN03733A IN3733DEN2015A IN2015DN03733A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A IN 3733DEN2015 A IN3733DEN2015 A IN 3733DEN2015A IN 2015DN03733 A IN2015DN03733 A IN 2015DN03733A
- Authority
- IN
- India
- Prior art keywords
- scaffold
- ester
- compound
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261725949P | 2012-11-13 | 2012-11-13 | |
| PCT/US2013/069686 WO2014078309A1 (en) | 2012-11-13 | 2013-11-12 | Cannabinoid receptor mediating compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03733A true IN2015DN03733A (enExample) | 2015-09-18 |
Family
ID=49725346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3733DEN2015 IN2015DN03733A (enExample) | 2012-11-13 | 2013-11-12 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US9765031B2 (enExample) |
| EP (1) | EP2919779B1 (enExample) |
| JP (1) | JP6272626B2 (enExample) |
| CN (1) | CN104884057B (enExample) |
| CA (1) | CA2889697C (enExample) |
| IN (1) | IN2015DN03733A (enExample) |
| WO (1) | WO2014078309A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765031B2 (en) | 2012-11-13 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| AU2015255765A1 (en) * | 2014-05-09 | 2016-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| WO2016196646A1 (en) * | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
| EP3423448B1 (en) * | 2016-03-04 | 2024-12-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Cannabinoid receptor mediating compounds |
| RU2703484C1 (ru) * | 2018-05-22 | 2019-10-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Способ производства безоболочных колбасок для функционального питания |
| KR20220156930A (ko) * | 2020-03-24 | 2022-11-28 | 인베르사고 파마 인코포레이티드 | 무정형 3,4-디페닐-4,5-디하이드로-1h-피라졸 유도체의 고체 분산체, 이를 포함하는 조성물 및 칸나비노이드 cb1 수용체 억제제로서의 이의 용도 |
| WO2021203195A1 (en) * | 2020-04-07 | 2021-10-14 | Inversago Pharma Inc. | Process for producing 4,5-dihydro-1h-pyrazoles and intermediates |
| CN118829427A (zh) * | 2022-02-24 | 2024-10-22 | 诺和诺德股份有限公司 | 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法 |
| IL314385A (en) * | 2022-03-14 | 2024-09-01 | Us Health | Cannabinoid receptor modulating compounds |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| CA1236641A (en) | 1984-07-06 | 1988-05-10 | Motoaki Tanaka | Copolymer of lactic acid and glycolic acid and method for producing same |
| JP2551756B2 (ja) | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
| HUP0204519A3 (en) * | 2000-03-23 | 2003-07-28 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing them and process for their preparations |
| SI1373216T1 (en) | 2001-03-22 | 2005-06-30 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| HUP0402113A3 (en) | 2001-09-21 | 2012-05-29 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof |
| KR100903760B1 (ko) * | 2001-09-21 | 2009-06-19 | 솔베이 파마슈티칼스 비. 브이 | Ｃｂ1-길항 작용을 가지는 신규한4,5-디하이드로-1ｈ-피라졸 유도체 |
| US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
| PL1713475T3 (pl) | 2004-01-30 | 2009-03-31 | Solvay Pharm Bv | 1,3,5-tripodstawione pochodne 4,5-dihydro-1-H-pirazolu wykazujące antagonistyczną aktywność w stosunku do CB1 |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
| ES2389569T3 (es) | 2006-05-05 | 2012-10-29 | Jenrin Discovery | Antagonistas/agonistas inversos de receptores de cannabinoides |
| US7655685B2 (en) | 2007-11-02 | 2010-02-02 | Jenrin Discovery, Inc. | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| WO2009074782A1 (en) | 2007-12-10 | 2009-06-18 | 7Tm Pharma A/S | Cannabinoid receptor modulators |
| US8288428B2 (en) | 2009-03-27 | 2012-10-16 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
| WO2011044370A1 (en) | 2009-10-07 | 2011-04-14 | Jenrin Discovery | Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes |
| JP5946192B2 (ja) * | 2010-11-18 | 2016-07-05 | ジェンリン ディスカバリーＪｅｎｒｉｎ Ｄｉｓｃｏｖｅｒｙ | 肥満症及び糖尿病を含む代謝性疾患の処置に有用なカンナビノイド受容体拮抗薬／逆作動薬 |
| US11155521B2 (en) * | 2012-11-13 | 2021-10-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| US9765031B2 (en) * | 2012-11-13 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cannabinoid receptor mediating compounds |
| AU2015255765A1 (en) | 2014-05-09 | 2016-11-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pyrazole derivatives and their use as cannabinoid receptor mediators |
| WO2016196646A1 (en) | 2015-06-04 | 2016-12-08 | The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services | Cannabinoid receptor mediating compounds |
-
2013
- 2013-11-12 US US14/442,383 patent/US9765031B2/en active Active
- 2013-11-12 WO PCT/US2013/069686 patent/WO2014078309A1/en not_active Ceased
- 2013-11-12 CA CA2889697A patent/CA2889697C/en active Active
- 2013-11-12 JP JP2015542015A patent/JP6272626B2/ja active Active
- 2013-11-12 IN IN3733DEN2015 patent/IN2015DN03733A/en unknown
- 2013-11-12 EP EP13802153.0A patent/EP2919779B1/en active Active
- 2013-11-12 CN CN201380069389.9A patent/CN104884057B/zh active Active
-
2017
- 2017-08-10 US US15/674,333 patent/US10787419B2/en active Active
- 2017-08-10 US US15/674,365 patent/US10683270B2/en active Active
-
2020
- 2020-05-08 US US16/870,093 patent/US11485709B2/en active Active
-
2022
- 2022-09-29 US US17/956,313 patent/US20230202983A1/en not_active Abandoned
-
2023
- 2023-02-10 US US18/108,264 patent/US11939297B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230202983A1 (en) | 2023-06-29 |
| CA2889697A1 (en) | 2014-05-22 |
| US10787419B2 (en) | 2020-09-29 |
| CN104884057A (zh) | 2015-09-02 |
| CA2889697C (en) | 2023-03-14 |
| US9765031B2 (en) | 2017-09-19 |
| EP2919779B1 (en) | 2021-01-06 |
| US20180022705A1 (en) | 2018-01-25 |
| US20230219896A1 (en) | 2023-07-13 |
| WO2014078309A1 (en) | 2014-05-22 |
| CN104884057B (zh) | 2019-08-20 |
| US11939297B2 (en) | 2024-03-26 |
| EP2919779A1 (en) | 2015-09-23 |
| JP2015536997A (ja) | 2015-12-24 |
| US20200331861A1 (en) | 2020-10-22 |
| US10683270B2 (en) | 2020-06-16 |
| WO2014078309A8 (en) | 2015-05-21 |
| US20180022706A1 (en) | 2018-01-25 |
| JP6272626B2 (ja) | 2018-01-31 |
| US20160039766A1 (en) | 2016-02-11 |
| US11485709B2 (en) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2023032I1 (en) | Deucravacitinib or a pharmaceutically acceptable salt thereof | |
| IN2015DN03733A (enExample) | ||
| NO2025034I1 (no) | Remdesivir or a pharmaceutically acceptable salt or ester thereof - forlengelse | |
| NO2022043I1 (en) | Asciminib or a pharmaceutically acceptable salt thereof, such as asciminib hydrochloride | |
| NO2021034I1 (no) | pemigatinib or a pharmaceutically acceptable salt thereof | |
| NO2021041I1 (no) | remimazolam or a pharmaceutically acceptable salt thereof | |
| EP2629786A4 (en) | COMPOSITIONS FOR THE ADMINISTRATION OF MEDICAMENTS | |
| PL2768479T3 (pl) | Zaróbki do kompozycji terapeutycznych zawierających nikotynę | |
| ZA201407726B (en) | Pharmaceutical compositions for combination therapy | |
| DK2632493T3 (da) | Lægemiddelindgivelsessammensætninger | |
| PL2560624T3 (pl) | Formulacja terapeutyczna do zmniejszania skutków ubocznych leku | |
| ZA201501977B (en) | Orally administered medical composition | |
| EP3082817A4 (en) | Compositions for drug administration | |
| IN2014MN02598A (enExample) | ||
| GB201216018D0 (en) | Pharmacologically active compounds | |
| IL231485A0 (en) | Medicinal compounds are immune to interference | |
| MY187718A (en) | Pharmaceutical formulations | |
| SMT201600341B (it) | Soluzione per somministrazione orale | |
| PL2672973T3 (pl) | Schemat podawania nitrokatecholi | |
| IL234363B (en) | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative | |
| EP2731605A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR RECTAL ADMINISTRATION | |
| IL229591A0 (en) | Addition of medicine | |
| LT2814473T (lt) | Farmacinės kompozicijos, skirtos derinių terapijai | |
| HUP1100641A2 (en) | A new diaza-benzofluoranthene derivate as drug | |
| DK2420219T3 (da) | Indgivelsesport |